Coulter finally resubmits Bexxar BLA

CLTR and partner SmithKline Beecham (SBH) resubmitted their BLA for Bexxar tositumoimab for the treatment of relapsed or refractory, low-grade or transformed low-grade B cell non-Hodgkin's lymphoma. C...